Eli Lilly and Co

Pfizer (PFE) is extensively conducting clinical trials for the label expansion of Ibrance.

In 2016, Pfizer’s (PFE) Ibrance reported revenues of ~$2.1 billion, compared with $723 million in 2015.

In 2016, Merck’s (MRK) Animal Health segment reported revenues of ~$3.5 billion, which reflected ~4% growth year-over-year.

The combined product sales of Bydureon and Byetta globally in 1Q17 was ~$199 million, which represents 1% YoY growth on a reported basis.

In 1Q17, AstraZeneca’s (AZN) Farxiga reported sales of $42 million in emerging markets, which equals year-over-year growth of ~100% on a reported basis.

In 1Q17, AstraZeneca’s leading sodium-glucose co-transporter 2 (or SGLT2) therapy for type-2 diabetes, Farxiga, reported revenues close to $270 million. This represents YoY growth of ~25% on a constant currency basis.

A look at Eli Lilly and Company Headquartered in Indianapolis, Indiana, Eli Lilly and Company (LLY) is a US pharmaceutical company focused on human pharmaceuticals and animal health. Stock price performance Eli Lilly’s stock price has fallen ~4.4% in 2Q17. However, the stock price had risen 10.9% year-to-date as of July 7, 2017. Analysts’ recommendations Wall […]

The combined revenues for Zetia and Vytorin fell 35% to $575 million in 1Q17, compared to $889 million in 1Q16.

Merck (MRK) launched Keytruda in 4Q14 and reported global sales of $584 million for 1Q17. As a result, the company reported ~134% growth in revenues compared to $249 million in 1Q16.

Pfizer Innovative Health contributed $7.4 billion, or about 58.0% of Pfizer’s total revenues in 1Q17.

As of June 20, 2017, Bristol-Myers Squibb was trading at a forward PE multiple of ~18.0x—compared to the industry average of 16.0x.

On June 15, 2017, Eli Lilly announced data from a study that evaluated the safety and efficacy of Taltz in patients with active psoriatic arthritis.

Pfizer (PFE) reported a 2% decline in revenues to ~$12.8 billion for 1Q17, as compared to $13.0 billion in 1Q16.

Elanco, Eli Lilly’s Animal Health business, reported growth of 2% to $769.4 million during 1Q17.

Revenues from Sanofi’s Established Prescription Products rose 0.6% at constant exchange rates during 1Q17 and reported revenues of ~2.6 billion euros in 1Q17.

In 1Q17, Amgen’s (AMGN) Nplate generated revenues of ~$154 million, which reflected a year-over-year growth rate of 9%.

In 1Q17, Zoetis’s (ZTS) dermatology portfolio reported revenues of ~$57 million, driven by the steady adoption of Cytopoint and Apoquel.

Zoetis (ZTS) has adopted a targeted R&D strategy that has resulted in multiple new product launches.

Eli Lilly & Co.’s (LLY) Animal Health company, Elanco, reported an increase of 2% in revenues to $769.4 million in 1Q17, compared to $754.6 million in 1Q16.

Wall Street analysts expect Pfizer’s (PFE) top line to rise 0.6% to ~$13.1 billion in 1Q17. Its earnings per share are expected to be $0.67 in the quarter.

Eli Lilly’s (LLY) human pharmaceutical segment contributes ~85.0% to Lilly’s total revenues.

The US healthcare system is unique in the developed world as it lacks a uniform system and, according to Emanuel, had been largely inefficient before Obamacare.

Eli Lilly (LLY) reported EPS (earnings per share) of $2.58 on revenue of $21.2 billion in 2016, compared to EPS of $2.26 on revenue of $20.0 million in 2015.

Sanofi’s (SNY) Established Prescription Products segment contributed nearly 30.5% of the company’s total revenues in 2016.

Pfizer (PFE) reported an 8% increase in revenues to $52.8 billion for 2016 as compared to $48.9 billion for 2015.

In 2016, Novartis’s (NVS) Cosentyx surpassed its closest competitor, Eli Lilly’s (LLY) Taltz, in number of total weekly prescriptions in the US market.

Keytruda, a prescription medicine classified under Merck’s (MRK) immunooncology franchise, is used to treat non-small cell lung cancer as well as melanoma.

Merck (MRK) reported a 1% increase in its revenues to $39.8 billion in 2016.

Novartis’s valuation has followed the industry’s overall trend over the last five years. Whether the healthcare sector’s valuation rises or falls, Novartis will definitely be affected.

Given the strong performance of Opdivo, Bristol-Myers Squibb’s Oncology segment emerged as its largest revenue contributor in 2016. The segment contributed ~35% of BMY’s total revenue.

Johnson & Johnson’s Medical Devices segment contributed nearly 35% to the company’s total revenues.

Incyte has classified its oncology product portfolio into targeted anti-cancer therapies and immuno-oncology or immunotherapies.

For 2016, Synagis reported 2% growth at constant exchange rates, following its 14% growth in sales in the US.

In 4Q16, Eli Lilly (LLY) reported Basaglar sales of $40 million from Japan and several European markets.

Sanofi’s (SNY) established prescription products contributed nearly 28.9% of the company’s total 4Q16 revenues.

Analysts expect an ~1.1% decline in Novartis’s (NVS) 4Q16 revenues to ~$12.4 billion following the effects of the acquisition and divestiture of several products.

AbbVie (ABBV) has completed enrollment in its Phase 3 pivotal trials testing investigational therapy risankizumab as a treatment option for psoriasis.

During the first nine months of 2016, Novo’s (NVO) new generation portfolio garnered 2.8 billion Danish kroner.

Novo’s (NVO) Victoza is a glucagon-like peptide-1 (or GLP-1) therapy for type 2 Diabetes patients.

During 3Q16, Novo’s sales in the US rose 2% in local currency terms to 14.2 billion Danish kroner.

On August 26, 2011, the FDA approved Pfizer’s (PFE) Xalkori for patients suffering from late-stage NSCLC and who express abnormal ALK gene.

Wall Street analysts estimate that Viagra’s sales in 2016 will reach approximately $1.6 billion, which would be a year-over-year (or YoY) decline of about 7.7%.

A Bloomberg survey of two brokerage houses on October 24, 2016, reflected a 50% “buy” rating and a 50% “hold” rating for the stock.

Novo Nordisk’s search for new molecules through partnerships and other alliances has proven instrumental in strengthening its R&D pipeline.

In addition to its robust drug portfolio, Novo Nordisk boasts a strong research pipeline in the diabetes, hemophilia, obesity, and growth disorder segments.

Insulin sales volumes sold across the world have grown at a compounded average growth rate (or CAGR) of 4.1% from May 2011 to May 2016.

Sanofi’s diabetes franchise includes Lantus, Toujeo, Amaryl, and Apidra. Lantus, a glargine insulin, contributed 17% of total revenues in fiscal 2015.

Sanofi is swapping its animal health business with Boehringer Ingelheim’s consumer healthcare business. The asset swap deal was signed on June 27, 2016.

Eli Lilly and Co.’s (LLY) overall business is classified into two business segments—Human Pharmaceuticals and Animal Health.

Currently being tested in six Phase 3 trials, ABT-494 is expected to be a significant improvement in the standard of care for rheumatoid arthritis.